Mariani A, Webb M J, Galli L, Podratz K C
Section of Gynecologic Surgery, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA.
Gynecol Oncol. 2000 Mar;76(3):348-56. doi: 10.1006/gyno.1999.5688.
The aim of this study was to assess the potential therapeutic role of para-aortic lymphadenectomy (PAL) in high-risk patients with endometrial cancer.
We studied two groups of patients with endometrial cancer who underwent operation at Mayo Clinic (Rochester, MN) during the interval 1984 to 1993: (1) 137 patients at high risk for para-aortic lymph node involvement (myometrial invasion >50%, palpable positive pelvic nodes, or positive adnexae), excluding stage IV disease, and (2) 51 patients with positive nodes (pelvic or para-aortic), excluding stage IV disease. By our definition, PAL required removal of five or more para-aortic nodes.
In both groups, no significant difference existed between patients who had PAL (PAL+) and those who did not (PAL-) in regard to clinical or pathologic variables, percentage irradiated, or surgical or radiation complications. Among the 137 high-risk patients, the 5-year progression-free survival was 62% and the 5-year overall survival was 71% for the PAL- group compared with 77 and 85%, respectively, for the PAL+ group (P = 0.12 and 0.06, respectively). For the 51 patients with positive nodes, the 5-year progression-free survival and 5-year overall survival for the PAL- group were 36 and 42% compared with 76 and 77% for the PAL+ group (P = 0.02 and 0.05, respectively). Lymph node recurrences were detected in 37% of the PAL- patients but in none of the PAL+ patients (P = 0.01). Multivariate analysis suggested that submission to PAL was a cogent predictor of progression-free survival (odds ratio = 0.25; P = 0.01) and overall survival (odds ratio = 0.23; P = 0.006).
These results suggest a potential therapeutic role for formal PAL in endometrial cancer.
本研究旨在评估主动脉旁淋巴结切除术(PAL)在高危子宫内膜癌患者中的潜在治疗作用。
我们研究了1984年至1993年间在梅奥诊所(明尼苏达州罗切斯特)接受手术的两组子宫内膜癌患者:(1)137例有主动脉旁淋巴结受累高危因素的患者(肌层浸润>50%、可触及的盆腔淋巴结阳性或附件阳性),不包括IV期疾病患者;(2)51例淋巴结阳性患者(盆腔或主动脉旁),不包括IV期疾病患者。根据我们的定义,PAL需要切除五个或更多的主动脉旁淋巴结。
在两组中,接受PAL(PAL+)的患者与未接受PAL(PAL-)的患者在临床或病理变量、照射百分比或手术或放疗并发症方面均无显著差异。在137例高危患者中,PAL-组的5年无进展生存率为62%,5年总生存率为71%,而PAL+组分别为77%和85%(P分别为0.12和0.06)。对于51例淋巴结阳性患者,PAL-组的5年无进展生存率和5年总生存率分别为36%和42%,而PAL+组分别为76%和77%(P分别为0.02和0.05)。PAL-患者中有37%检测到淋巴结复发,而PAL+患者中无一例出现(P = 0.01)。多变量分析表明,接受PAL是无进展生存率(优势比 = 0.25;P = 0.01)和总生存率(优势比 = 0.23;P = 0.006)的有力预测因素。
这些结果表明正规的PAL在子宫内膜癌中具有潜在的治疗作用。